Background: Obesity has become a serious global public health challenge, given that it leads to various adverse health outcomes that include cardiovascular illnesses, diabetes, and certain types of cancer. The World H...Background: Obesity has become a serious global public health challenge, given that it leads to various adverse health outcomes that include cardiovascular illnesses, diabetes, and certain types of cancer. The World Health Organization (WHO) has estimated that, at the end of 2022, 1 out of every 8 individuals were obese, and that the global adult obesity rates have over doubled since 1990, even as the adolescent obesity rates have quadrupled. Thus, as of 2022, nearly 2.5 billion adults, aged 18 years and above, were overweight, with 890 million being obese. Obesity and overweight incidence rate has been gradually increasing over the years, presenting significant challenges to the healthcare systems throughout the globe. In this regard, the objective of this systematic review was to evaluate the effectiveness and safety of lifestyle modifications (diet and physical activity) and pharmacotherapy in promoting weight loss and improving metabolic health in overweight adults. Methodology: To attain the above stated study objective, a systematic evaluation of previous studies was carried out, particularly studies that assessed the effectiveness and safety of lifestyle modifications (diet and physical activity) and pharmacotherapy in promoting weight loss and improving metabolic health in overweight adults. The authors have used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) in the selection of eligible studies for inclusion in the study. Results: The findings indicate that lifestyle interventions resulted in 5% - 10% weight reduction and significant improvements in metabolic indicators, while pharmacotherapy (GLP-1 receptor agonists) achieved up to 15% weight reduction and considerable metabolic health benefits. Further, comparative studies show lifestyle modifications provide overall health benefits, while medication is necessary for non-responders. Conclusion: Individualized treatment strategies are crucial, and further research is needed on long-term consequences and combination thera展开更多
目的:二甲双胍联合甘精胰岛素治疗2型糖尿病伴睡眠障碍患者临床疗效、糖代谢及睡眠质量的影响。方法:选取2019年3月至2022年3月安溪县中医院收治的口服降糖药物后效果不理想的2型糖尿病患者121例作为研究对象,按照不同治疗方法将患者分...目的:二甲双胍联合甘精胰岛素治疗2型糖尿病伴睡眠障碍患者临床疗效、糖代谢及睡眠质量的影响。方法:选取2019年3月至2022年3月安溪县中医院收治的口服降糖药物后效果不理想的2型糖尿病患者121例作为研究对象,按照不同治疗方法将患者分为对照组和观察组,其中对照组55例,观察组66例。对照组给予二甲双胍治疗,观察组给予二甲双胍联合甘精胰岛素治疗。采用匹兹堡睡眠质量指数量表(PSQI)比较2组患者干预前后睡眠质量的变化,比较2组血糖值相关指标对比:包括餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹血糖(FBG)、FBG达标时间、胰岛素总用量及总注射次数等,并比较并发症发生情况。结果:治疗后,观察组治疗后餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹血糖(FBG)、FBG达标时间、胰岛素总用量、总注射次数均低于对照组,观察组并发症发生率、PSQI评分均显著低于对照组,2组比较差异有统计学意义(P<0.05)。结论:针对2型糖尿病患者应用二甲双胍联合甘精胰岛素治疗有较满意的临床疗效,可有效改善患者睡眠障碍,降低血糖水平,减少并发症的发生,值得临床推广应用。展开更多
文摘Background: Obesity has become a serious global public health challenge, given that it leads to various adverse health outcomes that include cardiovascular illnesses, diabetes, and certain types of cancer. The World Health Organization (WHO) has estimated that, at the end of 2022, 1 out of every 8 individuals were obese, and that the global adult obesity rates have over doubled since 1990, even as the adolescent obesity rates have quadrupled. Thus, as of 2022, nearly 2.5 billion adults, aged 18 years and above, were overweight, with 890 million being obese. Obesity and overweight incidence rate has been gradually increasing over the years, presenting significant challenges to the healthcare systems throughout the globe. In this regard, the objective of this systematic review was to evaluate the effectiveness and safety of lifestyle modifications (diet and physical activity) and pharmacotherapy in promoting weight loss and improving metabolic health in overweight adults. Methodology: To attain the above stated study objective, a systematic evaluation of previous studies was carried out, particularly studies that assessed the effectiveness and safety of lifestyle modifications (diet and physical activity) and pharmacotherapy in promoting weight loss and improving metabolic health in overweight adults. The authors have used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) in the selection of eligible studies for inclusion in the study. Results: The findings indicate that lifestyle interventions resulted in 5% - 10% weight reduction and significant improvements in metabolic indicators, while pharmacotherapy (GLP-1 receptor agonists) achieved up to 15% weight reduction and considerable metabolic health benefits. Further, comparative studies show lifestyle modifications provide overall health benefits, while medication is necessary for non-responders. Conclusion: Individualized treatment strategies are crucial, and further research is needed on long-term consequences and combination thera
文摘目的:二甲双胍联合甘精胰岛素治疗2型糖尿病伴睡眠障碍患者临床疗效、糖代谢及睡眠质量的影响。方法:选取2019年3月至2022年3月安溪县中医院收治的口服降糖药物后效果不理想的2型糖尿病患者121例作为研究对象,按照不同治疗方法将患者分为对照组和观察组,其中对照组55例,观察组66例。对照组给予二甲双胍治疗,观察组给予二甲双胍联合甘精胰岛素治疗。采用匹兹堡睡眠质量指数量表(PSQI)比较2组患者干预前后睡眠质量的变化,比较2组血糖值相关指标对比:包括餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹血糖(FBG)、FBG达标时间、胰岛素总用量及总注射次数等,并比较并发症发生情况。结果:治疗后,观察组治疗后餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹血糖(FBG)、FBG达标时间、胰岛素总用量、总注射次数均低于对照组,观察组并发症发生率、PSQI评分均显著低于对照组,2组比较差异有统计学意义(P<0.05)。结论:针对2型糖尿病患者应用二甲双胍联合甘精胰岛素治疗有较满意的临床疗效,可有效改善患者睡眠障碍,降低血糖水平,减少并发症的发生,值得临床推广应用。
